An Overview of the Phase 3 Trial Assessing Lutetium Lu 177 Dotatate for Midgut Neuroendocrine Tumors

Video

Jonathan Strosberg, MD, section head of the Neuroendocrine Tumor Program and vice president of Medical Oncology at the Moffitt Cancer Center, gives an overview of the phase 3 trial assessing lutetium Lu 177 dotatate for midgut neuroendocrine tumors.

Pharmacy Times interviewed Jonathan Strosberg, MD, a professor of medical oncology, section head of the Neuroendocrine Tumor Program, and vice president of Medical Oncology at the Moffitt Cancer Center, on his presentation at the 2021 ASCO Annual Meeting about the NETTER-1 phase 3 trial of lutetium Lu 177 dotatate (Lutathera, Novartis) for midgut neuroendocrine tumors.

During the discussion, Strosberg gave an overview of the focus of the phase 3 trial assessing lutetium Lu 177 dotatate as a treatment for patients with midgut neuroendocrine tumors.

Related Videos
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba | stock.adobe.com
Ozempic, obesity, drug shortage, media portrayal | Image Credit: zimmytws - stock.adobe.com
Doctor using a stethoscope checking patient with examining, presenting results symptom and recommend treatment method, Healthcare and medical concept - Image credit: Ngampol | stock.adobe.com
Collaborative Care Team for Diabetes, Cardiovascular Disease | Image Credit: Production Perig - stock.adobe.com
Sleep Apenea C-PAP Machine | Image Credit: sbw19 - stock.adobe.com
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
Rear view of Audience listening Speakers on the stage in the conference hall or seminar meeting, business and education about investment concept -  Image credit: THANANIT | stock.adobe.com
Pharmacist helping patient use glucose monitor -- Image credit: Kalyakan | stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.